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The causative agents of rabies are single-stranded, negative-sense RNA viruses in the genus Lyssavirus of Rhabdoviridae, consisting
of twelve classified and three as yet unclassified species including classical rabies virus (RABV). Highly neurotropic RABV causes
rapidly progressive encephalomyelitis with nearly invariable fatal outcome. Rapid and reliable diagnosis of rabies is highly relevant
for public and veterinary health. Due to growing variety of the genus Lyssavirus observed, the development of suitable molecular
assays for diagnosis and differentiation is challenging. This work focused on the establishment of a suitable real-time RT-PCR
technique for rabies diagnosis as a complement to fluorescent antibody test and rabies tissue culture infection test as gold standard
for diagnosis and confirmation.The real-time RT-PCRwas adapted with the goal to detect the whole spectrum of lyssavirus species,
for nine of which synthesized DNA fragments were used. For the detection of species, seven probes were developed. Serial dilutions
of the rabies virus strain CVS-11 showed a 100-fold higher sensitivity of real-time PCR compared to heminested RT-PCR. Using a
panel of thirty-one lyssaviruses representing four species, the suitability of the protocol could be shown. Phylogenetic analysis of
the sequences obtained by heminested PCR allowed correct classification of all viruses used.
1. Introduction
Rabies diagnosis is based on fluorescent antibody testing
(FAT) in brain smears and inoculation of brain suspension
either inmouse neuroblastoma cell cultures or intracerebrally
in mice as confirmatory assays with high sensitivity and
specificity for postmortem diagnosis [1–3]. These techniques
arewell suited for rapid and reliable routine diagnosis, if brain
material is available. For other diagnostic specimens sampled
intra vitam in case of clinical suspicion, for example, saliva,
cerebrospinal fluid, or skin biopsies, more suited molecular
techniqueswith excellent sensitivity have been developed and
validated, mostly targeting the conserved nucleoprotein gene
of the lyssavirus genome, for example, [4–10]. Among these,
there are protocols both for classical RT-PCR and for real-
time RT-PCR, which adds speed, efficiency, contamination
safety, and reliability to the technique combined with the
potential to quantify the viral load [11, 12]. Amajor advantage
offered by these molecular techniques is the characterisation
of viral isolates by sequencing the given amplification prod-
ucts followed by phylogenetic or phylogeographic analysis
[13–15]. The greatest challenge for these powerful novel
techniques is the ever growing spectrum of known lyssavirus
species/genotypes (GT), probably all of which having the
potential to cause animal and human rabies fatalities [16, 17].
So far, 12 lyssavirus species and three as yet unclassified
species have been identified [17].The development of classical
simple or (hemi)nested RT-PCR methods with particular
emphasis on the diagnosis of a broad spectrumof lyssaviruses
species has been published in a number of studies [18–
23]. Also several real-time RT-PCR protocols suited for the
broad detection or differentiation of several genotypes have
been developed [9, 24–28]. The work of Wakeley et al.
[25] is of particular interest for the rabies epidemiology in
Europe concerning the European bat lyssaviruses types 1 and
2 [29–32] apart from classical rabies [33, 34]. This assay uses
genotype (GT) specific probes and fluorophore signals for
direct differentiation of GT1, GT5, and GT6 in a single-tube
reaction. The protocol proposed by Nadin-Davis et al. [8] is
highly suited for the detection of a broad range of classical
rabies viruses.
The goal of this work was, based on a comprehensive
review of the rich literature on the theme and adapting
thereof, to develop, establish, and validate classical and
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real-time RT-PCR protocols for (intravitam) diagnosis of
rabies and molecular-epidemiological characterisation of
viral strains with the main emphasis on the growing number
of known species/genotypes.
2. Materials and Methods
2.1. Samples
2.1.1. Cell Culture Supernatant of Viral Strains. All operations
with potentially infectiousmaterial apart from centrifugation
in closed tubes were performed in a class II biological
safety cabinet. Frozen cell culture supernatants of rabies
virus strains propagated previously on BHK-21 cells (baby
hamster kidney cells, ATCC, Manassas, USA) were thawed,
centrifuged at 2,000 g for 10min at 4∘C, and filtrated using
the Millex-HA 450 nm Filter (Millipore, Cork, Ireland).
2.1.2. Brain Suspension. Approximately 1 g of cerebellum,
medulla oblongata, and hippocampus from unfixed, freshly
obtained brain material was homogenized to a 20% brain
suspension using a mortar and pestle, after addition of
approximately 1 g of quartz sand (Merck KGaA, Darmstadt,
Germany) and 5mL of Modified Eagle Medium with Earle’s
salts with 2.2 g/L NaHCO
3
(Bioswisstec AG, Schaffhausen,
Switzerland) supplemented with 5% penicillin 10,000 IU/mL
(Bioswisstec AG, Schaffhausen, Switzerland) and 20% foetal
calf serum (FCS; PAA Laboratories GmbH, Pasching, Aus-
tria). The suspension was then decanted into a 5mL tube
(5mL Polystyrene Round-Bottom Tube; BD Biosciences,
Erembodegem, Belgium) to let it sediment for 1 hour at
4∘C and subsequently centrifuged at 1,400 g for 10min and
filtrated as above. Frozen brain suspensions from former
mouse inoculation tests [39] were handled like frozen cell
culture supernatant.
2.1.3. Saliva and Oral Swabs. 500𝜇L of RNA Storage Solution
(Ambion, Foster City, USA)was added to 100–200𝜇L of fresh
or previously frozen saliva samples or swabs, which were
subsequently vortexed (Vortex Genie 2, TEWIS Laborbedarf
AG, Berne, Switzerland) for 1min and centrifuged in a
Biofuge Pico (Heraeus Holding GmbH, Hanau, Germany) at
5,000 rpm for 10min.
2.1.4. Cerebrospinal Fluid. Cerebrospinal fluid (CSF) samples
were diluted 1 : 2 to 1 : 4 with RNA Storage Solution (Ambion,
Foster City, USA).
2.1.5. Skin Biopsies. Skin biopsies were shaved, cut into small
pieces with a sterile pair of scissors, and further processed as
described for brain suspension.
2.2. Viral Strains and Propagation in Cell Culture. A panel
of 31 lyssaviruses (including 4 species) was used to test
the diagnostic performance of our PCR (Table 1). Stocks of
viral strains were produced in neuroblastoma cells (MNA
42/13) as described for the rabies tissue culture infection
test (RTCIT, described below). The maintenance medium
used for the first passage was Dulbecco’s MEM supple-
mented with 0.5% neomycin 50 IU/mL (Bioswisstec AG,
Schaffhausen, Switzerland), 5% tryptose phosphate (BioCon-
cept Ltd. Amimed, Allschwil, Switzerland), 1% nonessen-
tial amino acids (Bioswisstec AG, Schaffhausen, Switzer-
land), 3% foetal calf serum, and 1% L-Glutamine 200mM
(Bioswisstec AG, Schaffhausen, Switzerland) to which 1%
Diethylaminoethyl-Dextran (DEAE-Dextran; Sigma-Aldrich
Corporation, St. Louis, USA) was added. Dulbecco’s MEM
with 10% foetal calf serum was used for the 3 consecutive
passages. Staining of the cells was performed after each
passage using Rabies DFA Reagent (Millipore, Livingston,
UK) as a conjugate.
2.3. FAT and RTCIT. The standard fluorescent antibody test
(FAT) was performed with brain tissue samples as previously
described [40]. Rabies tissue culture infection test (RTCIT)
using four consecutive passages on murine neuroblastoma
cells [41–43] was applied to clinical specimens like brain
specimens, liquor, saliva, or skin biopsies.
2.4. Primers, Probes, and Synthetic DNA. Primers, probes,
and synthetic DNA were obtained from Microsynth (Micro-
synth GmbH, Balgach, Switzerland). The location of suit-
able N-directed primers and probes for heminested RT-
PCR and real-time RT-PCR, respectively, was chosen and
evaluated based on published work [8, 18, 22, 25]. Using
multiple sequence alignment (ClustalX 2.0.3 program [44–
46]) of the N gene region of the available lyssavirus
species RABV (33 sequences), LBV (4 sequences), MOKV
(5 sequences), DUVV (4 sequences), EBLV-1 (17 sequences),
EBLV-2 (14 sequences), ABLV, Aravan, Khujand, Irkut, and
West Caucasian bat (each one) from GenBank (National
Center for Biotechnology Information and National Library
of Medicine, Rockville Pike, USA), variable positions of
primers and probes were adjusted with wobble positions
for a potentially broader match. Alternatively, primers with
singlewobbles or substitutionsweremixed. Several probes for
real-time RT-PCR for broadening the spectrum of detectable
species were designed in this work (Table 2). As internal
control for conventional RT-PCR, amplification of GAPDH
(glyceraldehyde 3-phosphate dehydrogenase) was used [37].
As internal inhibition control for real-time RT-PCR, primers
and probes for the amplification of Sendai virus (ATCC,
Manassas, USA [38]), which was added to the samples before
RNA isolation, were used (Table 2).
Synthetic DNA with a length of 125 bases encompassing
positions 48–172 according to the Pasteur virus genome
(X03673) of the following lyssavirus species were obtained
from Microsynth: Aravan virus (ARAV) EF614259, Khujand
virus (KHUV) EF614261, Bokeloh bat lyssavirus (BBLV)
JF311903, Australian bat lyssavirus (ABLV) AF418014, Irkut
virus (IRKV) EF614260, Lagos bat virus (LBV) EU293110,
Mokola virus (MOKV) 293117, Shimoni bat virus (SHIV)
GU170201, andWest Caucasian bat virus (WCBV) EF614258.
2.5. RNA Extraction. RNA was isolated from 140 𝜇L of
sample supernatant using the QIAamp Viral RNA Mini Kit
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(QIAGEN, Germantown, USA) according to the manufac-
turer’s instructions, except the usage of RNA Storage Solution
(Ambion, Foster City, USA) for elution. Extracted RNA was
stored at −20∘C until use.
2.6. Heminested RT-PCR. Heminested RT-PCR was per-
formed as previously described [22] using the OneStep RT-
PCR Kit. Briefly, for the first round 3 𝜇L of extracted RNA
was amplified in the RT-PCR mix prepared according to
manufacturer’s instructions, supplemented with 0.6 𝜇M of
each primer (JW12-F, JW6AS1-R1, and JW6AS2-R1; Table 2)
and 5U RNase inhibitor (RNasin Plus, 40U/𝜇L; Promega,
Madison, USA), with the following cycling conditions: 50∘C
for 30min and 95∘ for 15min for reverse transcription and
subsequent activation of the polymerase, followed by 10 cycles
of 95∘C for 20 s, 60∘C for 30 s (1∘C decrease/cycle), followed
by 72∘C for 30 s and 35 cycles of 95∘C for 20 s, 52∘C for 30 s,
followed by 72∘C for 30 s. For the second round, the TaqDNA
Polymerase Kit (QIAGEN, Germantown, USA) was used
with 2 𝜇L of the first round product, 2.5 𝜇L 10x PCR buffer,
1.2mM final dNTP concentration (Invitrogen, Foster City,
USA), 0.4 𝜇M of heminested primers (JW12-F, JW10AS1-R2,
and JW10AS2-R2; Table 2), 0.5U of Taq DNA polymerase,
and 19.35 𝜇L Nuclease Free Water (Ambion, Foster City,
USA). Cycling conditions were as follows: 95∘C for 5min
followed by 35 cycles of 94∘C for 20 s, 52∘C for 20 s, followed
by 72∘C for 30 s. Amplifications were performed in a 2720
Thermal Cycler. Internal controls using GAPDH primers, as
described in the one-round PCR, were run in parallel in the
first round.
2.7. Gel Electrophoresis for Sequencing. Gel electrophoresis
was performedusing a 1.5%TAE agarose gel (agarose LE, ana-
lytical grade; Promega,Madison,USA) stainedwith ethidium
bromide (Eurobio, Courtaboeuf, France). For sequencing, the
desired band was excised under UV light [47].
2.8. Real-Time RT-PCR (NDWD). Real-time RT-PCR
(NDWD) adapted fromNadin-Davis et al. andWakeley et al.
[8, 25] was performed using the QuantiTect Probe RT-PCR
Kit (QIAGEN, Germantown, USA). The 25 𝜇L reaction
volume consisted of 9.5 𝜇L RNase-free water, or 9 𝜇L in the
multiplex mix, 12.5 𝜇L 2x QuantiTect RT-PCR Master Mix,
0.25 𝜇L of the RABVD1 forward and reverse primer (0.4 𝜇M
final concentration each), 0.25𝜇L of the probes RABVD1,
LysGT5, and LysGT6 together in the multiplex mix or
0.25 𝜇L of the probes ivvWCBV-P, ivvMok-P, ivvABLV2n-P,
ivvLBV-P, ivvKhujand-P, and ivvSBLV2-P (Table 2) alone in
a mix (all 0.2 𝜇M final concentration), 0.25𝜇L of QuantiTect
RT Mix, and 2 𝜇L of sample RNA. Additionally, for the
internal Sendai virus control, 5 𝜇L of sample RNA was
added to a mix containing 6.625 𝜇L of RNase-free water,
12.5 𝜇L 2x QuantiTect RT-PCR Master Mix, 0.625 𝜇L of
Sendai forward primer, reverse primer, and probe mix
(Sendai-F, Sendai-R, and Sendai-P, 8 𝜇M; Table 2), and
0.25 𝜇L of QuantiTect RT Mix. The reactions were carried
out in MicroAmp Fast Optical 96-Well Reaction Plates with
Barcode 0.1mL (Applied Biosystems, Foster City, USA) in a
7500 Fast Real-Time PCR System v1.3.1 (Applied Biosystems,
Foster City, USA) using the following cycling conditions: 1
cycle of 50∘C for 30min and 95∘C for 15min followed by 45
cycles of 95∘C for 15 sec and 50∘C for 1min. Amplification
curve analysis was performed using the 7500 Software v2.0.6
(Applied Biosystems, Foster City, USA).
2.9. Cloning for Analytical Sensitivity Analysis. For cloning,
a segment of viral genome covering a part of the N gene
(positions 1–933 according to the Pasteur virus genome
accession number X03673) of CVS-11 was generated using
primers designed for this purpose (TWclon-F and TWclon-
R, Table 2). Amplification was performed using the OneStep
RT-PCR Kit with the master mix consisting of 29.25𝜇L of
RNase-free water, 10 𝜇L 5xQIAGENOneStep RT-PCR buffer,
0.4mM of each dNTP, 0.6 𝜇M of the cloning primers, 10U
RNasin (40U/𝜇L), and 2 𝜇L of QIAGEN OneStep RT-PCR
Enzyme mixed with 5 𝜇L of extracted RNA to a total volume
of 50𝜇L. Amplifications were performed in a Veriti 96-Well
Thermal Cycler (Applied Biosystems, Foster City, USA) using
the following cycling conditions: 30min at 50∘C, followed by
15min at 95∘C and 40 repetitive cycles of 1min at 94∘C, 1min
with a temperature gradient from 56∘C to 46∘C in steps of
2∘C, and 1min at 72∘C. Elongation at 72∘Cwas extended for 10
additional minutes in the last cycle. After gel electrophoresis
excised PCR fragments with a length of 933 bp were eluted
with the QIAquick Gel Extraction Kit (QIAGEN, German-
town, USA) and cloned into the pCR-II-TOPO vector using
the TOPO TA Cloning Kit (Invitrogen, Foster City, USA)
according to the manufacturer’s instructions.
2.10. Sequencing. Sequencing reactions were performed by
MicrosynthAG, Balgach, Switzerland. For this purpose, reac-
tion mixtures containing 22.5 ng DNA per 100 bp, 30 pmol of
each primer used for the amplification (Table 2), and DEPC
treated water (Ambion, Foster City, USA) to a final volume
of 15 𝜇L were prepared. Sequences were edited using the
SeqMan II v5.01 Software (DNASTAR, Madison, USA) and
subsequently evaluated using the Clone Manager 9 software
(Scientific & Educational Software, Cary, USA).
2.11. Phylogenetic Reconstruction. The 543 bp nucleotide
sequences of the nucleoprotein gene obtained from the hem-
inested PCR reaction, together with additional sequences
retrieved from GenBank, were saved in Fasta file format.
The sequences were then aligned using the ClustalX 2.0.3
Software and theGeneDoc Software v2.5.0 [48]. Phylogenetic
trees were constructed with the MEGA5 software using
Kimura 2-parameter distances [35].
3. Results
3.1. Cell Culture. Thirty-one lyssaviruses (19x RABV, 7x
EBLV-1, 4x EBLV-2, and 1x DUVV) were analysed in RTCIT.
All isolates were viable in murine neuroblastoma cells and
could be visualized using Rabies DFA Reagent as a conjugate.
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Figure 1: Amplification of a CVS-11 serial dilution using hnRT-
PCR. Ethidium bromide stained gel after amplification of the CVS-
11 strain using dilutions from 10−1 to 10−8 (A–H). The amplification
product of 582 bp is clearly visible up to a dilution of 10−5 (lane E).
Ladder = standard for determination of amplification product size.
3.2. Sensitivity of PCR Methods. For the comparison with
infectious titres, RNA of the classical rabies virus strain CVS-
11 was extracted from cell culture supernatants (BHK-21 cells
or neuroblastoma cells MNA 42/13) and serially diluted from
10−1 to 10−8. The infectious titre was determined according to
the Spearman-Karber formula [49, 50] in fluorescent focus
forming doses 50% (FFD
50
). In the heminested RT-PCR
(hnRT-PCR), the amplification product of 582 bp was visible
up to a dilution of 10−5 corresponding to a detection limit of
0.4 FFD
50
(10−0.4 FFD
50
; Figure 1). In the real-time RT-PCR
(NDWD) the serial dilution was performed in triplicate. The
limit of detection was defined as the last dilution at which at
least 2 out of 3 replicates were positive. Using this definition,
CVS-11 was detectable up to a dilution of 10−7 (once at
a dilution of 10−8). The amplification plot showed regular
intervals of the curves with CT-values from 18.1 (dilution
10−1) to 40.0 (dilution 10−7). Relating to infectious titre real-
timeRT-PCR reached a detection limit of 0.003 FFD
50
(10−2.6)
for CVS-11.
The efficiency of the real-time RT-PCR (NDWD) was
determined using linear regression of the CT-values and the
titres of the samples (Figure 2). On the basis of the slope
coefficient, the efficiency can be inversely derived as 𝐸 =
10
(−1/slope coefficient)
− 1. The efficiency for CVS-11 was 94.5%
with a slope coefficient of −3.46.
3.3. Analytical Sensitivity. The limit of detection in terms of
DNA copy numbers was determined using 10-fold serial dilu-
tions of a cloned 933 bp segment of N of CVS-11 containing
106 to 100 DNA copies/PCR reaction. In the hnPCR, the limit
of detection was 100 DNA copies/3𝜇L of starting material of
the CVS-11 plasmid. In the real-time PCR (NDWD), the 10-
fold serial dilution of theCVS-plasmidwas tested in triplicate.
The limit of detection was 10 DNA copies/2 𝜇L of the CVS-11
plasmid with CT-values between 38.6 and 47.5.The efficiency
was at 82.8% with a slope coefficient of −3.82 (not shown).
The intra-assay repeatability of the real-time PCR (NDWD)
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Figure 2: Efficiency of the real-time RT-PCR (NDWD). The linear
regression of the CT-values (ordinate) and the titres of serially
diluted CVS-11 (abscissa) exhibited a slope coefficient of −3.46
corresponding to an efficiency of 94.5% (𝐸 = 10(−1/slope coefficient) − 1).
proved to be excellent with very low coefficients of variation
up to 102 DNA copies (0.18–1.37%) with and outlier at 101
copies (12.05%; Table 3).
3.4. Diagnostic Broadness of PCR Methods. A total of 31
lyssaviruses (19 identified as classical RABV, 7 as EBLV-
1, 4 as EBLV-2, and 1 as DUVV) were used to test the
diagnostic performance of the PCR (Table 1). All viruses used
were detected with the expected band size in the hnRT-
PCR technique (Table 4). The specificity of the amplified
product was confirmed as RABV, EBLV-1, EBLV-2, or DUVV
by sequencing in each case. Host GAPDH (glyceraldehyde
3-phosphate dehydrogenase) was detected in all of the cell
culture supernatants and mouse brain suspensions as inter-
nal control, indicating that sample material was present
and RNA isolation, reverse transcription, and amplification
were not inhibited. All samples were also tested positive
by the real-time RT-PCR assay (Table 4). Sendai virus as
internal control for inhibition was run in parallel using the
same cycling conditions. In the real-time RT-PCR (NDWD)
with an annealing temperature of 50∘C, some samples were
detected with more than one probe. With the exception
of the sample derived from a raccoon dog from Poland,
the probe for the homologous genotype always yielded the
lowest CT-value. In this exceptional case, the probe for the
detection of genotype 6 was slightly lower than the one
for genotype 1 (15.0 versus 16.1; Table 4). Comparison of
these two probes with the sequence of the rabies variant
in question showed 1 and 2 mismatches with the RABVD1-
P and LysGT6-P probe, respectively (Figure 3). Duvenhage
virus, also designated as genotype 4, was detectable with
the probe adapted for genotype 6 in spite of 3 mismatches
(LysGT6-P).Theprobe LysGT6-Pwas able to detect synthetic
DNA fragments of BBLV, ARAV, and IRKV, although con-
taining one or two mismatches, respectively. The synthetic
DNA fragments of KHUV, ABLV, LBV, MOKV, SHIBV, and
WCBV, which exhibited from four (ABLV/KHUV) up to
ten (WCBV) mismatches to the best fitting probe for GT1,
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Table 3: Serial dilutions of the CVS-11 plasmid in real-time PCR (NDWD).
Dilution Copy numbers/2 𝜇L CT-value 1 CT-value 2 CT-value 3 Mean ± SD CV (%)
10−1 106 22.6 22.0 22.4 22.3 ± 0.31 1.37
10−2 105 25.1 25.2 25.3 25.2 ± 0.10 0.40
10−3 104 29.1 28.8 28.7 28.9 ± 0.21 0.72
10−4 103 32.9 32.9 32.8 32.9 ± 0.06 0.18
10−5 102 36.4 36.2 35.9 36.2 ± 0.25 0.70
10−6 101 47.5 38.6 39.0 41.7 ± 5.03 12.05
10−7 100 — — — — —
SD: standard deviation; CV: coefficient of variation.
Table 4: PCR-results of rabies viruses tested.
Real-time RT-PCR (NDWD)
Sample Species hnRT-PCR CT-valuea
FAM (GT1) YY (GT5) Cy5 (GT6)
1 Bat Stade (1970) EBLV-1 + 14.7 17.3
2 Bat Hamburg RV 9 (1968) EBLV-1 + 20.2 14.8 16.4
3 Bat Finland RV 8 (1986) EBLV-2 + 15.1
4 Bat Holland RV 31 EBLV-1 + 20.2 14.7 16.8
5 Dog Tunisia (1986) RABV + 24.6 27.2 33.2
6 Bat Spain RV 119 EBLV-1 + 33.4 27.6 31.6
7 Bat Florida RABV + 24.2 41.6
8 Bat Denmark EBLV-1 + 26.5 21.1 22.4
9 Raccoon dog Poland (1985) RABV + 16.1 15.0
10 Raccoon Florida (1986) RABV + 25.8
11 Bat Chile RV 108 RABV + 14.4
12 Jackal Zimbabwe RABV + 14.6
13 Cattle Zimbabwe RABV + 18.0
14 Canada Red Fox RABV + 17.9
15 LEP (Flury, 1939) RABV + 17.7
16 HEP (Flury) RABV + 28.5
17 Dog Nepal Nr. 96 RABV + 21.7
18 Sri Lanka dog 121 (1986) RABV + 23.2
19 Eurofox 912/87 RABV + 28.3
20 Duvenhage RV6 DUVV + 27.0
21 NYC 58 RABV + 16.5
22 Dog Lima RABV + 20.0
23 Bat Bremerhaven RV11 EBLV-1 + 27.0
24 Bat B24 EBLV-1 + 16.9 20.6
25 Skunk Canada RABV + 23.2
26 SAD Bern, 1935 RABV + 18.8
27 CSSR/A-virus RABV + 18.5
28 Challenge virus standard (CVS-11) ATCC VR 959 RABV + 19.8
29 TW 1814/92 EBLV-2 +
30 TW 1392/93 EBLV-2 +
31 TW 118/02 EBLV-2 +
aOnly for samples with positive reaction.
FAM: 6-carboxyfluorescein reporter dye, to detect RABV (GT1); YY: Yakima Yellow, to detect EBLV-1 (GT5); Cy5: Cyanine 5, to detect EBLV-2 (GT6); ND:
not done.
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Figure 3: Alignment of probes RABVD1-P (a) and LysGT6-P (b) with a RABV strain isolated from a raccoon dog from Poland. Matches
in nondegenerated positions are displayed as dots. Matches in wobbled positions are highlighted in yellow. Mismatches are highlighted in
turquoise.
GT6, or GT5, respectively, were all detected with the corre-
sponding species-specific new probe (Table 2). 105.2 copies
of the synthetic DNA were detected at CT-values of 27.9–
33.5 for ABLV, MOKV, SHIBV, and WCBV (not shown). The
efficiency of detection of KHUV, which showed an atypical
amplification plot at the highest number of 1010.2 copies of
the synthetic DNA, and that of LBV was lower with CT-
values of 40.0 and 40.5 at a copy number of 105.2, respectively
(not shown). Multiplexing of combinations of these probes
(ivvLBV-P (FAM: 6-carboxyfluorescein), ivvKhujand-P (YY:
Yakima Yellow), and ivvSBLV2-P (Cy5: Cyanine 5), as well
as ivvWCBV-P (FAM), ivvMok-P (YY), and ivvABLV2n-P
(Cy5)) as for the species 1, 5, and 6 was not successful.
3.5. Sequencing of Amplification Products and Phylogenetic
Analysis. The 543 bp amplification products of the nucle-
oprotein gene obtained in the heminested PCR reactions
were sequenced (Table 1) and analysed phylogenetically with
additional sequences retrieved from GenBank represent-
ing all known lyssaviruses. The similarity of the 543 bp
nucleotide sequences of the nucleoprotein gene (positions
74–616 according to the Pasteur virus genome) among the
lyssaviruses included ranged from64.6% to 90.1% (Hamming
distance). Similarity at the amino acid level was 68.0–95%.
The resulting phylogenetic tree obtained by the neighbor-
joining method implemented in the MEGA5 software is
presented in Figure 4. All known genotypes were resolved
with high bootstrap confidence with our samples grouping
expectedly.
3.6. Clinical Specimens. Clinical specimens like brain sus-
pensions (1x human, 12x mouse), skin biopsies from the
nape of the neck (3x human, 1x mouse), saliva (4x human),
and cerebrospinal fluids (6x human) were used for the
establishment of the assays. Both hnRT-PCR and real-time
RT-PCR (NDWD) were shown to work properly on all
these samples without significant inhibition usingGAPDHas
internal control for conventional RT-PCR and Sendai virus
for real-time RT-PCR (NDWD), which was mixed to the
samples before RNA isolation. Skin biopsies taken from the
neck and lip of a mouse (white Swiss mouse at an age of 3
weeks) euthanized 2 weeks after intracerebral infection with
SAD Bern virus 20 years ago were positive with the hnRT-
PCR and real-time PCR (NDWD). Skin biopsies taken from
other locations on the head were positive with the real-time
PCR (NDWD) and weakly positive in hnRT-PCR whereas
samples taken around the vibrissae were weakly positive in
real-time PCR (NDWD) only. Sequencing of amplification
products excluded a contamination with the positive CVS-11
control (not shown).
Brain suspension from an imported human rabies case
in 2012 was already strongly positive after one round of the
hnRT-PCR. Phylogenetic analysis of the 543 bp nucleotide
fragment revealed its close relationship to the classical rabies
virus strains circulating in the insectivorous Mexican free-
tailed bat, Tadarida brasiliensis, a species common in the
southern United States and Mexico. This allowed identifica-
tion of the origin of the patient’s infection, who had travelled
extensively and did not report any previous biting incident
[51, 52].
4. Discussion
Based on a large amount of published work, we were able
to establish and quantitatively characterise RT-PCR proto-
cols for the detection of lyssaviruses in clinical samples.
Well suited real-time protocols [8, 25] for the detection of
classical rabies virus and the genotypes 5 and 6 (EBLV-1
and EBLV-2) were adapted and extended for the detection
of at least 13 lyssavirus species. To this goal, 6 species-
specific probes (KHUV, ABLV, LBV, MOKV, SHIBV, and
WCBV) were designed and verified on synthetic DNA frag-
ments encompassing the targeted sequence of the lyssaviral
nucleoprotein gene. Multiplexing the probes in a single-tube
reaction as described for the genotypes 1, 5, and 6 was not
possible with the newly designed probes, probably due to
false priming and/or interference within the mix of reagents
and synthetic target sequence [53]. As far as evaluated with
the multiplexed probes for the genotypes 1, 5, and 6 using 31
viral isolates, which were all detectable with high sensitivity,
direct differentiation of targeted genotypes on the base of
the quantitative reaction (CT-values) was mostly possible.
Furthermore, a single probe for genotype 6 (species EBLV-2)
was able to detect up to 7 genotypes/species.We consider this
type of cross hybridization as an advantage of the technique
using degenerate primers and probes in terms of a broad
detectability of lyssavirus rather than a lack of accuracy of
discrimination. In an approach using SYBRGreen qPCRwith
similarly degenerate primers spanning the same part of N
as in this work [28], the detection of all lyssavirus species
known at that time was achieved. Using several genotype-
specific probes in a TaqMan real-time protocol, we were
able to add more intrinsic confidence to the specificity of
the analysis [54]. Quantitative characterisation of the assay
using the probe for genotypes 1, 5, and 6 on CVS-11 showed
excellent sensitivity and repeatability with a detection limit
of as low as an infectious dose of 0.003 FFD
50
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Figure 4: Phylogenetic tree with 543 bp fragments of N. Phylogenetic tree obtained with MEGA5 software [35]. The length of branches
(horizontal lines) corresponds to phylogenetic distance between different sequences (scale bar in substitutions per site). Numbers proximal
to nodes indicate bootstrap confidence of subjacent groups. Lyssavirus strains used in this study are depicted in red. Sequences are given with
GenBank or own designation followed by the two-letter country code and a two-letter code for the source species as follows: Bt, bat; Ca, cat;
Ci, African civet; Dg, dog; Fx, fox; Hu, human; Jc, jackal; Ra, raccoon; Rd, raccoon dog; Ro, rodent; Sh, shrew; Sk, skunk, except for Pa, cSAD,
and CV, which are standing for Pasteur strain, Street Alabama Dufferin strain, and challenge virus standard, respectively. The currently used
abbreviations for species are shown next to the tree. RABV, rabies virus; ABLV, Australian bat lyssavirus; WCBV, West Caucasian bat virus;
IKOV, Ikoma virus; LLEBV, Lleida bat lyssavirus; MOKV, Mokola virus; SHIBV, Shimoni bat virus; LBV, Lagos bat virus; KHUV, Khujand
virus; BBLV, Bokeloh bat lyssavirus; ARAV, Aravan virus; DUVV, Duvenhage virus; EBLV, European bat lyssavirus; IRKV, Irkut virus.
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with an analytical sensitivity of 10 DNA copies at efficiencies
of 94.5% and 82.8%, respectively. Considering the amount
of degeneration in both primers and probes, the efficiencies
determined must be considered satisfactory. As far as the
absolute detection limit in terms of target copies is concerned,
the usage of plasmid DNA rather than RNA must be kept in
mind. Since reverse transcription cannot be assumed as 100%
efficient and reproducible [55], the limit for RNA might be
somewhat lower.
For further characterisation of samples with a posi-
tive reaction in real-time RT-PCR, excellent simple and
(hemi)nested RT-PCR protocols are available. With the
protocol used for this work [22], all 31 viral strains used
could be amplified and sequenced, confirming the diagnostic
broadness of the assay. Phylogenetic analysis of these partial
nucleotide sequences belonging to genotypes 1, 4, 5, and
6 along with known sequences confirmed the suitability
of this relatively conserved genomic region for molecular-
epidemiological characterisation of lyssaviruses circulating
worldwide [56–58].This was also confirmed in the context of
a human rabies case imported to Switzerland in 2012, which
could be attributed unequivocally to an exposure to a bat of
the species Tadarida brasiliensis in California, USA.
5. Conclusion
In this work we could show and validate the suitability of an
adapted and further developed real-time RT-PCR protocol
for the rapid, efficient, andhighly sensitive intravitamdiagno-
sis of a wide spectrum of lyssavirus species followed by rapid
molecular-epidemiological characterisation of viral isolates
respective to origin of the virus and source of exposure,
using heminested RT-PCR. This new tool is also particularly
promising for active surveillance of European bat lyssaviruses
using oral swabs in live-captured bats.
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